Regeneron Pharmaceuticals Inc insider trading
REGNfinancial statementsForm 4 filings on EDGAR204 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Regeneron Pharmaceuticals Inc bought $0 of stock in the open market, and 4 sold $7M. Officers and directors accounted for $0 of purchases and $7M of sales. The last reported transaction was an open-market sale by Murphy Andrew J on October 14, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 15, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $7MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
204 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 6 | $753.76 | $5K | 51,974 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 35 | $755.91 | $26K | 51,939 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 16 | $757.68 | $12K | 51,923 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 24 | $758.16 | $18K | 51,899 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 14 | $759.96 | $11K | 51,885 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 74 | $760.65 | $56K | 51,811 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 27 | $761.36 | $21K | 51,784 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 55 | $762.57 | $42K | 51,729 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 25 | $763.76 | $19K | 51,704 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 219 | $764.40 | $167K | 51,485 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 271 | $765.39 | $207K | 51,214 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 279 | $766.47 | $214K | 50,935 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 192 | $767.39 | $147K | 50,743 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 105 | $768.33 | $81K | 50,638 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 127 | $769.30 | $98K | 50,511 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 12 | $770.20 | $9K | 50,499 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 283 | $771.56 | $218K | 50,216 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 211 | $772.56 | $163K | 50,005 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 224 | $773.40 | $173K | 49,781 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 121 | $774.48 | $94K | 49,660 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 376 | $775.46 | $292K | 49,284 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 66 | $776.31 | $51K | 49,218 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 38 | $777.76 | $30K | 49,180 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 454 | $778.64 | $354K | 48,726 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 380 | $779.59 | $296K | 48,346 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 463 | $780.63 | $361K | 47,883 | Oct 15, 2026 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | open-market sale10b5-1 | 50 | $781.47 | $39K | 47,833 | Oct 15, 2026 |
| Oct 13, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | option exercise | 17,000 | $381.92 | $6M | 64,833 | Oct 15, 2026 |
| Oct 13, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | tax withholding | 12,853 | $754.58 | $10M | 51,980 | Oct 15, 2026 |
| Sep 3, 2026 | McCourt Marion | EVP Commercial | open-market sale10b5-1 | 1,131 | $857.39 | $970K | 12,003 | Sep 3, 2026 |
| Sep 2, 2026 | McCourt Marion | EVP Commercial | open-market sale10b5-1 | 1,215 | $850.00 | $1M | 13,134 | Sep 3, 2026 |
| Sep 2, 2026 | Guarini Kathryn | Director | option exercise | 400 | $719.37 | $288K | 1,003 | Sep 3, 2026 |
| Sep 2, 2026 | Guarini Kathryn | Director | open-market sale10b5-1 | 400 | $850.00 | $340K | 603 | Sep 3, 2026 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | option exercise | 12,282 | $381.92 | $5M | 45,392 | Aug 21, 2026 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | tax withholding | 9,019 | $830.15 | $7M | 36,373 | Aug 21, 2026 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | option exercise | 6,283 | $381.92 | $2M | 24,583 | Aug 20, 2026 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | tax withholding | 4,599 | $813.47 | $4M | 19,984 | Aug 20, 2026 |
| Aug 10, 2026 | Guarini Kathryn | Director | option exercise | 400 | $719.37 | $288K | 1,003 | Aug 12, 2026 |
| Aug 10, 2026 | Guarini Kathryn | Director | open-market sale10b5-1 | 400 | $800.00 | $320K | 603 | Aug 12, 2026 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | option exercise | 800 | $376.69 | $301K | 2,503 | Aug 12, 2026 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | open-market sale10b5-1 | 800 | $800.00 | $640K | 1,703 | Aug 12, 2026 |
| Jul 2, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 200 | $650.15 | $130K | 17,303 | Jul 7, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 5 | $701.76 | $4K | 17,598 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 15 | $702.46 | $11K | 17,583 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 24 | $703.46 | $17K | 17,559 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 15 | $704.28 | $11K | 17,544 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 14 | $705.56 | $10K | 17,530 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 7 | $706.74 | $5K | 17,523 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 4 | $707.40 | $3K | 17,519 | May 4, 2026 |
| May 1, 2026 | Ryan Arthur F | Director | open-market sale10b5-1 | 6 | $709.45 | $4K | 17,513 | May 4, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Murphy Andrew J | Co-Chief Scientific Officer | Oct 14, 2026 | open-market sale | 51,974 | — | $3M (27) | 27 of 27 |
| McCourt Marion | EVP Commercial | Sep 3, 2026 | open-market sale | 12,003 | — | $2M (2) | 2 of 2 |
| Zoghbi Huda Y | Director | Aug 10, 2026 | option exercise | 2,503 | — | $2M (12) | 12 of 12 |
| Pitofsky Jason | SVP Controller | Feb 9, 2026 | open-market sale | 5,767 | — | $2M (12) | 11 of 12 |
| Bassler Bonnie L | Director | Jan 7, 2026 | open-market sale | 1,703 | — | $2M (2) | 2 of 2 |
| Guarini Kathryn | Director | Sep 2, 2026 | option exercise | 1,003 | — | $660K (2) | 2 of 2 |
| Ryan Arthur F | Director | Jul 2, 2026 | open-market sale | 17,303 | — | $435K (48) | 48 of 48 |
| Poon Christine A | Director | Jan 2, 2026 | award | 5,219 | — | — | — |
| Larosa Joseph J | EVP General Counsel and Secret | Aug 19, 2026 | option exercise | 45,392 | — | — | — |
| Fenimore Christopher R. | EVP Finance CFO | Aug 18, 2026 | option exercise | 24,583 | — | — | — |
| Sing George L | Director | Jan 2, 2026 | award | 31,007 | — | — | — |
| Van Plew Daniel P | EVP & General Mgr, Industrial | Dec 9, 2025 | tax withholding | 21,673 | — | — | — |
| Yancopoulos George | Bd. Co-Chair, President & CSO, Director | Dec 31, 2025 | option exercise | 339,030 | — | — | — |
| Schleifer Leonard S | Bd. Co-Chair, President & CEO, Director | Dec 31, 2025 | tax withholding | 214,523 | — | — | — |
| Thompson Craig B. | Director | Jan 2, 2026 | award | 775 | — | — | — |
| Schenkein David P | Director | Jan 2, 2026 | award | 603 | — | — | — |
| Goldstein Joseph L | Director | Jan 2, 2026 | award | 6,703 | — | — | — |
| Coles N Anthony | Director | Jan 2, 2026 | award | 1,714 | — | — | — |
| Brown Michael S | Director | Jan 2, 2026 | award | 1,703 | — | — | — |
| Stahl Neil | EVP Research and Development | Dec 16, 2024 | tax withholding | 48,829 | — | — | — |
Questions
Are Regeneron Pharmaceuticals Inc insiders buying or selling?
Over the twelve months to November 1, 2026, 7 insiders at Regeneron Pharmaceuticals Inc sold $12M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $12M. Only open-market purchases and sales are counted.
Who sold the most Regeneron Pharmaceuticals Inc stock in the last year?
Murphy Andrew J (Co-Chief Scientific Officer) sold $3M in 27 open-market sales over the twelve months to November 1, 2026.
Do Regeneron Pharmaceuticals Inc executives sell under 10b5-1 plans?
104 of the 105 open-market sales in the last twelve months (99%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Regeneron Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.